EICHOR
● Completed
TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment
Condition: Pulmonary Tuberculosis · Sponsor: Centers for Disease Control and Prevention
About this study
This Phase 2, multicenter, open-label clinical trial evaluated the antimicrobial activity and safety of rifapentine-containing regimens during the intensive phase of pulmonary tuberculosis treatment. Participants were randomized to receive either a standard rifampin-based regimen (RHZE) or a rifapentine-substituted regimen (PHZE). An extension study evaluated higher daily doses of rifapentine (10, 15, and 20 mg/kg). The primary endpoint was sputum culture conversion at 8 weeks. Secondary outcomes included time to culture conversion, safety, and treatment discontinuation.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (29)
| Central Arkansas Veterans Health System | Little Rock, Arkansas, United States | — |
| LA County/USC Medical Center | Los Angeles, California, United States | — |
| University of Southern California Medical Center | Los Angeles, California, United States | — |
| University of California at San Diego | San Diego, California, United States | — |
| University of California, San Francincisco | San Francisco, California, United States | — |
| Denver Department of Public Health and Hospitals | Denver, Colorado, United States | — |
| Washington DC Veterans Administration Medical Center | Washington D.C., District of Columbia, United States | — |
| Emory University School of Medicine | Atlanta, Georgia, United States | — |
| Chicago VA Medical Center (Lakeside) | Chicago, Illinois, United States | — |
| Northwestern University | Chicago, Illinois, United States | — |
| Hines VA Medical Center | Hines, Illinois, United States | — |
| Johns Hopkins University School of Medicine | Baltimore, Maryland, United States | — |
+ 17 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.